Quick-reference tables summarizing pivotal trial data for approved immunotherapy agents for GI cancer. Add a tag
SCION Workshop Feb. 11–14, 2025 in Austin, Tx applications open April 22 The Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) Workshop is an intimate immunotherapy clinical trial development program, led by experts in the field who are equipped to help their assigned students navigate through the unique considerations that accompany immunotherapy treatments. Application Submissions Open April 22, 2024 Application Submissions Close July 22, 2024 Applicants Notified September 18, 2024 Small Group Virtual Pre-Meeting January (Day/Time TBD) About SCION Designed to address the unique considerations for designing clinical trial protocols focused on cancer immunotherapy, the SCION Workshop connects participants with experienced faculty in the field and dedicated patient advocates to advise on clinical trial protocol development
The Society for Immunotherapy of Cancer (SITC) hosted the 2021 SITC Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, virtually on February 22-24, 2021. Available here are the presentation slides and video from Monday, February 22, 2021
22 attachments
See matching library entry files - Meeting: 2021 SITC Cancer Immunotherapy Winter S...
On behalf of the society and the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group, we are pleased to announce the publication of a new manuscript “Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease” in the Journal for ImmunoTherapy of Cancer. While intratumoral immunotherapies have the potential to boost anti-tumor immune responses to overcome immunosuppressive tumor microenvironments, phase III trials evaluating them in late-stage disease have had limited success to-date, in part due to the complex nature of these trials not fully adapted to assess local therapies. The aim of this manuscript is to provide guidance on how to design trials with the greatest likelihood of demonstrating the benefits of intratumoral immunotherapy across all stages of pathogenesis, and ultimately bring more effective treatment options to patients. Expert Panel Recommendations for Trial Design To address challenges in intratumoral immunotherapy clinical trial design, an Expert Panel comprised of an international group of leaders from academia and industry convened to develop guidance on a variety of design elements including: • Patient stratification factors • Exclusion criteria • Study arm considerations • Optimal endpoints • Response assessment • Patient populations to prioritize Supplemental Guidance on Localized Therapy Administration In addition, the manuscript also provides an illustrated supplement that instructs users on the proper administration of localized immunotherapies for solid tumors and lymphomas, subcutaneous lymph nodes from lymphoma or metastatic tumors, accessible head and neck, liver, and breast lesions, and intravesical immunotherapy
IO Clinical Trials is part of the IO360˚ conference and is a great one day program for clinical trial operation professionals
02-08-2018 | 08:30 - 18:30 ET New York NY
SITC Recommendations on Intratumoral Immunotherapy Clinical Trial (IICT) Design On behalf of the society and the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group, we are pleased to announce the publication of a new manuscript “Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease ” in the Journal for ImmunoTherapy of Cancer. While intratumoral immunotherapies have the potential to boost anti-tumor immune responses to overcome immunosuppressive tumor microenvironments, phase III trials evaluating them in late-stage disease have had limited success to-date, in part due to the complex nature of these trials not fully adapted to assess local therapies. The aim of this manuscript is to provide guidance on how to design trials with the greatest likelihood of demonstrating the benefits of intratumoral immunotherapy across all stages of pathogenesis, and ultimately bring more effective treatment options to patients. Key Recommendations: Patient stratification factors Exclusion criteria Study arm considerations Optimal endpoints Response assessment Patient populations to prioritize Expert Panel Recommendations for Trial Design To address challenges in intratumoral immunotherapy clinical trial design, an Expert Panel comprised of an international group of leaders from academia and industry convened to develop guidance on a variety of design elements tailored to different stages of cancer development—from pre-malignant to unresectable/metastatic—that can maximize the chance of capturing the effect of intratumoral immunotherapies.
Richard Pazdur: On February 22, 2017, the U.S. Food and Drug Administration approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant
Friday, Sept. 22, 2017 From the Society for Immunotherapy of Cancer In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us